Portal vein thrombosis (PVT) represents a well-known complication during the natural
course of liver cirrhosis (LC), ranging from asymptomatic cases to life-threating conditions …

In real-world clinical practice, the acceptance of anticoagulation therapy in the management
of portal vein thrombosis (PVT) in patients with cirrhosis is limited by the fear of an increased …

Purpose To determine whether posttransjugular intrahepatic portosystemic shunt (TIPS)
placement anticoagulation therapy could benefit patients with cirrhosis and portal vein …

Background Patients with cirrhosis have a high incidence of portal vein thrombosis (PVT),
and optimal management of PVT in cirrhotic patients remains unclear. Currently, there is no …

Direct-acting oral anticoagulants (DOACs) have provided benefit in patients requiring
anticoagulation for certain diseases by decreasing the burden of subcutaneous injections …

Abstract Background & Aims Portal vein thrombosis (PVT) is frequently observed in cirrhosis
and may be a clinically important complication. In vitro assays for endogenous thrombin …

Abstract Background and Aim Progression of liver disease in cirrhosis is associated with an
increased incidence of portal vein thrombosis (PVT) in cirrhosis. However, evidence …

Nontumoral portal vein thrombosis (PVT) is an increasingly recognized complication in
patients with cirrhosis. Substantial evidence shows that portal flow stasis, complex …

Background Portal vein thrombosis (PVT) leads to significant morbidity and mortality burden
in patients with cirrhosis. An improved understanding of the utility of anticoagulation in …

Purpose To assess the effects of preexisting nonmalignant portal vein thrombosis (PVT) on
mortality, clinical relapse, shunt dysfunction, and overt hepatic encephalopathy (HE) after …